edit

Trophoblast glycoprotein
Identifiers
Symbols	TPBG; 5T4; 5T4-AG; M6P1
External IDs	OMIM: 190920 MGI: 1341264 HomoloGene: 4859
Gene ontology Molecular function • protein binding Cellular component • integral to plasma membrane • membrane Biological process • cell motility • cell adhesion
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	7162	21983
Ensembl	ENSG00000146242	ENSMUSG00000035274
UniProt	Q13641	Q3UPI2
RefSeq	NM_006670 (mRNA)	NM_011627 (mRNA)
	NP_006661 (protein)	NP_035757 (protein)
Location	Chr 6: 83.13 - 83.14 Mb	Chr 9: 85.64 - 85.64 Mb
PubMed search	[1]	[2]

5T4 is an antigen expressed in a number of carcinomas. It is an N-glycosylated transmembrane 72 kDa glycoprotein containing seven leucine-rich repeat regions. 5T4 is often referred to as an oncofetal antigen due to its expression in foetal trophoblast (where it was first discovered) or trophoblast glycoprotein (TPBG).

5T4 is found in tumors including the colorectal, ovarian, and gastric. Its expression is used as a prognostic aid in these cases. It has very limited expression in normal tissue but is widespread in malignant tumors throughout their development.

Its confined expression appears to give 5T4 the potential to be useful in cancer immunotherapy. There has been extensive research into its role in antibody-directed immunotherapy through the use of the high-affinity murine monoclonal antibody, mAb5T4, to deliver response modifiers (such as staphylococcus aureus superantigen) accurately to a tumor.

5T4 is also the target of the cancer vaccine TroVax which is used in the treatment of colorectal cancer.